Valuation : Mymetics Corporation

Market Cap 439K 377K 355K 324K 604K 41.6M 608K 4.21M 1.63M 21.26M 1.65M 1.61M 67.66M P/E 2021
-1.86x
P/E 2022 -1.77x
Enterprise Value 72.12M 62.01M 58.34M 53.24M 99.35M 6.84B 99.87M 691M 267M 3.49B 271M 265M 11.12B EV / Sales 2021
177x
EV / Sales 2022 78x
Free-Float
99.88%
Yield 2021 *
-
Yield 2022 -
1 day+45.45%
1 week+1,066,566.67%
Current month+1,066,566.67%
1 month+1,066,566.67%
3 months+1,066,566.67%
6 months+1,066,566.67%
Current year+1,066,566.67%
Current year 0
Extreme 0.0003
3.2
1 year 0
Extreme 0.0003
3.2
3 years 0
Extreme 0.0003
5.6
5 years 0
Extreme 0.0003
230
10 years 0
Extreme 0.0003
380
Manager TitleAgeSince
Chief Executive Officer 58 19/11/2012
Change 5-day change 1-year change 3-year change Capi.($)
+45.45%+1,066,566.67%+1,066,566.67%-40.74% 45
+2.02%+1.26%+41.37%+105.18% 69.19B
-1.16%-4.89%+31.22%+74.21% 62.97B
-1.11%+2.78%-14.86%+375.59% 27.27B
-4.92%-3.22%-3.90%-17.87% 24.78B
-0.93%-0.81%+29.69%+14.38% 25.8B
+0.12%-0.18%+23.42%-16.24% 20.11B
+6.04%+7.25%+233.25%+383.12% 18.47B
-1.43%-2.43%-8.12%+515.88% 14.88B
-2.27%+1.37%+53.01%+160.83% 14.29B
Average +4.19%+0.66%+106,695.17%+155.43% 27.78B
Weighted average by Cap. -0.15%+0.11%+37.83%+139.85%

Financials

2021 2022
Net sales 430K 370K 348K 317K 592K 40.77M 595K 4.12M 1.59M 20.84M 1.61M 1.58M 66.31M 1.03M 884K 832K 759K 1.42M 97.46M 1.42M 9.85M 3.81M 49.81M 3.86M 3.78M 159M
Net income -4.73M -4.07M -3.83M -3.49M -6.52M -448M -6.55M -45.33M -17.54M -229M -17.76M -17.37M -729M -4.8M -4.13M -3.89M -3.55M -6.62M -456M -6.65M -46.05M -17.82M -233M -18.04M -17.65M -741M
Net Debt 67.1M 57.69M 54.28M 49.53M 92.44M 6.36B 92.91M 643M 249M 3.25B 252M 246M 10.35B 71.68M 61.63M 57.98M 52.92M 98.75M 6.8B 99.26M 687M 266M 3.47B 269M 263M 11.05B
Logo Mymetics Corporation
Mymetics Corporation is a vaccine company. The Company is focused on developing vaccines for infectious diseases. The Company has over five vaccine candidates in its pipeline: human immunodeficiency virus type 1 (HIV-1)/acquired immune deficiency syndrome (AIDS), intra nasal Influenza, Malaria, Herpes Simplex Virus (HSV) and the Respiratory Syncitial Virus (RSV) vaccine. Its technology utilizes virosomes, lipid-based carriers containing functional fusion viral proteins and natural membrane proteins, in combination with rationally designed antigens. Its prophylactic HIV-1 vaccine candidate is constituted of virosomes linked to conserved antigens derived from the HIV-1 glycoprotein 41 (gp41) proteins from the clade B. The RSV vaccine consists of the reconstituted membrane of RSV containing the native viral proteins. The HSV vaccine candidate consists of the reconstituted membrane of HSV-1 or HSV-2. The intranasal influenza vaccine includes the reconstituted membrane of influenza virus.
Employees
-
  1. Stock Market
  2. Stocks
  3. MYMX Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!